Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. G. Nicholson, J. Behr, K. K. Brown, R. M. du Bois, T. E. King, Jr, G. Raghu, K. D. Jones (London, United Kingdom; Munich, Germany; Denver, CO, San Francisco, CA, Seattle, WA, United States Of America). Effect of bosentan in patients with confirmed usual interstitial pneumonia (UIP) on surgical lung biopsy (SLB): subset analysis of the randomised, controlled BUILD 1 trial in IPF. Eur Respir J 2007; 30: Suppl. 51, 783

Member's Comments

No comment yet.

Related content which might interest you: Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Pirfenidone in unclassifiable ILD (uILD): subgroup analysis of patients with/without a surgical lung biopsy (SLB) Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis? Year: 2020 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 The effects of T-PEP on ventilation lung scan in patients with bronchiectasis: Protocol for a randomized controlled trial Source: Annual Congress 2010 - Respiratory muscle function and training in acute and chronic respiratory disease Year: 2010 Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT) Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 LATE-BREAKING ABSTRACT: A multicenter, prospective, randomized, controlled trial of endobronchial valve therapy vs standard of care in homogeneous emphysema (IMPACT) Source: International Congress 2016 – Endoscopic lung volume reduction I Year: 2016 Acute effects of supplemental oxygen therapy (SOT) using different nasal cannulas on walking capacity in patients with idiopathic pulmonary fibrosis (IPF) – a randomized cross-over trial Source: International Congress 2019 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2019 STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results Source: International Congress 2016 – Endoscopic lung volume reduction I Year: 2016 The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Videothoracoscopic lung biopsy (VATS-LB) in the diagnosis of diffuse interstitial lung disease (DILD) and evaluation of an outpatient surgical approach. A prospective multicentric study Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 The effect of azithromycin on sputum inflammatory markers in bronchiectasis – analysis of a randomized controlled trial Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 The effect of radical treatment and pulmonary rehabilitation on muscle mass as measured with CT-scan: A randomised trial in patients (pts) with lung cancer and mesothelioma Source: Annual Congress 2012 - Exercise and physical activity: towards evidence-based benefits in different populations Year: 2012